Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a me ...